Clinical Trials on Refractory Anemia With Excess Blasts in Russian Federation
Total 4 results
-
Onconova Therapeutics, Inc.TerminatedMyelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEBUnited States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
-
National Research Center for Hematology, RussiaUnknownSeptic Shock | Nonchemotherapy Drug-induced Neutropenia | Neutropenia After Chemotherapy in Oncohematological Patients | Neutropenia in Patients With Aplastic AnemiaRussian Federation
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast CancerSpain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama